KCM
VNDA icon

Kennedy Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Kennedy Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.65M Buy
239,481
+4,312
+2% +$33.3K 0.04% 439
2025
Q4 		$2.07M Sell
235,169
-1,476
-0.6% -$8.12K 0.04% 420
2025
Q3 		$1.18M Sell
236,645
-823
-0.3% -$3.81K 0.03% 491
2025
Q2 		$1.12M Buy
237,468
+17,020
+8% +$74.4K 0.03% 498
2025
Q1 		$1.01M Sell
220,448
-873
-0.4% -$4.07K 0.02% 516
2024
Q4 		$1.06M Sell
221,321
-4,875
-2% -$23.4K 0.02% 592
2024
Q3 		$1.06M Sell
226,196
-2,869
-1% -$15.4K 0.02% 588
2024
Q2 		$1.29M Buy
+229,065
New +$1.18M 0.03% 564
2016
Q4 		– Sell
-206,327
Closed -$3.43M – 764
2016
Q3 		$3.43M Buy
+206,327
New +$2.78M 0.07% 473
2015
Q3 		– Sell
-210,462
Closed -$2.67M – 749
2015
Q2 		$2.67M Sell
210,462
-185,608
-47% -$2M 0.05% 541
2015
Q1 		$3.68M Buy
+396,070
New +$4.48M 0.06% 472

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's VNDA Position: Q1 2026 in Review

Kennedy Capital Management increased its Vanda Pharmaceuticals (VNDA) stake by 1.8% in Q1 2026, buying an estimated $33.3K and bringing the position to 239,481 shares worth $1.65M. The position accounts for 0.04% of the portfolio, ranked #439.

Kennedy Capital Management first reported a position in VNDA in Q1 2015 and has held it in 11 quarters since. The position peaked at $3.68M in Q1 2015. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Kennedy Capital Management held 239,481 shares of Vanda Pharmaceuticals worth $1.65M as of Q1 2026.
  • Kennedy Capital Management bought 4,312 Vanda Pharmaceuticals shares in Q1 2026, an estimated $33.3K.
  • Vanda Pharmaceuticals made up 0.04% of Kennedy Capital Management's portfolio in Q1 2026, its #439 holding.
  • Kennedy Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2015 and has held it in 11 quarters since.
  • Kennedy Capital Management's Vanda Pharmaceuticals position peaked at $3.68M in Q1 2015.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.